brivaracetam Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

brivaracetam / Generic mfg.

NCT05109234 / 2020-002769-33: A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Active, not recruiting

Europe, US, RoW

Brivaracetam Film-coated tablet, Brivaracetam oral solution

UCB Biopharma SRL

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

02/25

NCT06315322: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Recruiting

120

Europe, US, RoW

Brivaracetam Film-coated tablet, Brivaracetam oral solution

UCB Biopharma SRL

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

03/30

NCT03250377: A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Enrolling by invitation

217

Japan, RoW

Brivaracetam, Briviact

UCB Biopharma SRL

Partial Seizures With or Without Secondary Generalization, Epilepsy

12/24

ChiCTR2400081880: A randomized controlled study of the efficacy and safety of brivaracetam as adjunctive therapy in the treatment of partial-onset seizures

Not yet recruiting

180

Placebo; Brivaracetam

West China Hospital of Sichuan University; West China Hospital of Sichuan University, To be updated

Partial epilepsy

NCT05639946: Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Active, not recruiting

brivaracetam, Placebo

University of Minnesota

Spinal Cord Injuries, Neuropathic Pain

08/24

01/28

NCT04715646 / 2020-003664-29: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Active, not recruiting

Europe, Japan, US, RoW

Brivaracetam, BRV, Briviact

UCB Biopharma SRL

Epilepsy

07/29

EXPAND, NCT04666610 / 2020-002750-24: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Recruiting

2/3

160

Europe, US, RoW

Brivaracetam, BRV, Placebo, PBO

UCB Biopharma SRL, UCB Biopharma SRL

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

02/27

NCT04836559 / 2020-003698-24: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Completed

110

Europe, US, RoW

JNJ-40411813, Placebo

Janssen Research & Development, LLC, Janssen Research and Development LLC, US

Focal Onset Seizures

02/24

NCT04379011: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

Completed

1/2

Brivaracetam, Briviact, Placebo

University of Minnesota

Spinal Cord Injuries

03/24

09/24

EHAD, NCT05899764: Epileptic Hippocampus in Alzheimer's Disease

Not yet recruiting

1/2

Brivaracetam, Briviact, Brivajoy

University of California, Los Angeles

Alzheimer Disease, Mild Cognitive Impairment

06/29

NCT05622370: An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Active, not recruiting

RoW

Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg

Overseas Pharmaceuticals, Ltd., GX pharma technology (beijing) Co., Ltd

Partial Seizure

03/23

NCT06312566: A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Completed

Japan

brivaracetam (BRV) tablet, BRV, Briviact, brivaracetam (BRV) dry syrup

UCB Biopharma SRL

Healthy Study Participants

06/24

NCT05029960: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Active, not recruiting

Brivaracetam

University of Rochester

Brain Tumor

08/25

NCT03517423: Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study

Completed

N/A

Canada

Brivaracetam, BRV

Centre hospitalier de l'Université de Montréal (CHUM), UCB Pharma

Epilepsy

12/22

08/23

PREP, NCT05180916: Priming the Epileptic Brain: tVNS to Improve Efficacy of add-on AED in Patients With Focal Epilepsy

Recruiting

N/A

Europe

TVNS

Eindhoven University of Technology, Clinical Trial Center Maastricht B.V.

Focal Epilepsy

07/23

NCT03532516: Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

Available

N/A

Brivaracetam, Briviact

UCB Biopharma SRL

Epilepsy

NCT05543122: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Completed

N/A

Canada

either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe, Typical brand names include, but not limited to: Tenoretic, Wellbutrin, Zyban, Briviact, Cipralex, Lexapro, Diflucan, Vimpat, Lamictal, Keppra, Trexall, Xatmep, Ezetrol, Nexlizet

The Hospital for Sick Children, St. Justine's Hospital, University of Waterloo

Breast Feeding

12/23

03/24



	Diseases Companies Products Productz Mechanisms of Action Sites